Ancillary exploratory studies of the randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of Tranilast on motor, respiratory, and cardiac function in patients with Duchenne muscular dystrophy aged 10 years and older, urinary titin and metabolome analysis

Ancillary exploratory studies of the randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of Tranilast on motor, respiratory, and cardiac function in patients with Duchenne muscular dystrophy aged 10 years and older, urinary titin and metabolome analysis - Ancillary exploratory studies of the TRPV2 inhibition therapy, urinary titin and metabolome analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054897

Enrollment

Registered

2024-07-08

Start date

2024-07-08

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne muscular dystrophy

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Participants of the randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of Tranilast on motor, respiratory, and cardiac function in patients with Duchenne muscular dystrophy aged 10 years and older

Exclusion criteria

Exclusion criteria: Non participants of the Randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of Tranilast on motor, respiratory, and cardiac function in patients with Duchenne muscular dystrophy aged 10 years and older

Design outcomes

Primary

Measure	Time frame
Urinary titin, PG metabolites	—

Countries

Japan

Contacts

Public ContactTsuyoshi Matsumura

NHO Osaka Toneyama Medical Center Neurology

matsumura.tsuyoshi.kq@mail.hosp.go.jp06-6853-2001

Outcome results